Pemivibart - Invivyd
Alternative Names: Pemgarda; VYD-222Latest Information Update: 05 Sep 2024
At a glance
- Originator Invivyd
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus attachment inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered COVID 2019 infections
Most Recent Events
- 03 Sep 2024 Updated pharmacodynamics data from a preclinical studies in COVID-2019 infections released by Invivyd
- 14 Jun 2024 Pharmacodynamics data from the preclinical studies in COVID-2019 infections released by Invivyd
- 31 May 2024 Invivyd announces intention to launch Pemivibart for COVID-2019 infections (Prevention) in USA (IV)